“Out of stock” does not settle the rules

Local stock and the national list differ

The US drug agency is called FDA, short for Food and Drug Administration.

FDA keeps a list of medicines in short supply across the country. One pharmacy running out does not mean a medicine is on that list. FDA guidance checked September 26, 2026.

Ask whether the explanation is about the official list or about a local supply problem. These are different questions.

The injection shortages were resolved

On December 19, 2024, FDA confirmed that the national shortage of tirzepatide injections had ended.

On February 21, 2025, FDA said the national shortage of semaglutide injections had ended.

Neither injection appeared on FDA’s shortage list when it was checked September 26, 2026.

Adding a vitamin may still count as copying

Adding vitamin B12 to a custom semaglutide medicine does not always stop it being counted as a copy of an available medicine. FDA guidance checked September 26, 2026.

The phrase “essentially a copy” means the medicine is close enough to an available product for the copying limits to apply. Ask why the proposed change matters for your health needs.

Ask for a current explanation

• Is this exact medicine on FDA’s shortage list now?
• Why does the law allow this custom medicine for me?
• Is that reason written in my visit record?